Founder @ Shaynly | AI Automation | Building Brands | SEO | AEO |

As the Founder of Shaynly, I have spent over five years advancing AI-driven brand marketing strategies to optimize visibility and campaign efficiency. By leveraging advanced SEO practices, our team achieved a 50% boost in brand visibility, while AI integration enhanced marketing campaign efficiency by 30%.  

My past leadership roles, including Global Marketing Director at Shaynly and Head of Business Strategy at Ferticare, have equipped me with expertise in strategic planning and process optimization. With a focus on marketing strategy, SEO, and AI, I remain committed to delivering innovative marketing solutions that empower brands to thrive in competitive markets.

Sivanandan N.

adherence.

Chief Optimus

Rosetta Omics

The goal at Rosetta Omics is to unlock the road to precision medicine by tumor characterization via high resolution proteomic profiling.
While Genomics provides the code, proteins are the primary functional and structural molecules of life.
https://rosettaomics.fr/

Member of the Board of Advisors

Institute of Adherence to Medication

Co-Founder

Chief Optimus @ the company called adherence. | Clinical Trials- endpoints and outcome measures | Evidence based medication adherence metrics | solutions for value based care

The Morisky Medication Adherence Scale (MMAS) is the gold-standard, validated tool for assessing medication adherence behavior through patient self-reporting, available in both 4-item (MMAS-4) and 8-item (MMAS-8) versions that measure both intentional and unintentional non-adherence. Developed by my father, Dr Donald Morisky, MMAS tools have been validated in hundreds of clinical studies, translated into over 170 languages, and integrated into various healthcare settings including hospitals, clinics, and digital health platforms as part of standard patient care protocols. Beyond simple assessment, the MMAS intellectual property library now serves as the foundation for predictive analytics and digital interventions, helping healthcare providers identify and address medication adherence challenges before they impact patient outcomes.

The digital transformation of MMAS has opened new frontiers in healthcare delivery. Hospital systems worldwide are integrating MMAS tools directly into their electronic health records, allowing for seamless assessment and monitoring of patient adherence. In outpatient settings, clinics are using digital MMAS implementations to track adherence patterns over time, enabling more targeted interventions. The integration into remote patient monitoring and chronic care management platforms has been particularly transformative, allowing healthcare providers to identify adherence issues before they lead to adverse outcomes.

The future of MMAS is being shaped by cutting-edge technologies and innovative approaches to healthcare delivery. Artificial intelligence and machine learning algorithms are being applied to MMAS data to develop predictive models that can identify patients at risk of non-adherence before problems arise. These models are being integrated into clinical decision support systems, helping healthcare providers make more informed decisions about patient care.

As healthcare continues to evolve, the MMAS intellectual property library stands as a model for how clinical innovation, technological advancement, and scientific validation can come together to address one of healthcare's most persistent challenges. Through continued development and strategic partnerships, Adherence is ensuring that MMAS tools will continue to play a crucial role in improving patient outcomes through better medication adherence for generations to come.

taplio

The Battle

Sivanandan N.

Philip Morisky, MBA

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?